Although the WNT/β-catenin signaling pathway is often constitutively activated in liver cancer, due to stabilizing β-catenin mutations, previous data indicate that an additional suppression of the WNT antagonist, particularly of SFRP1, through epigenetic mechanisms is an important event in cancer formation (Kaur et al. 2012). The gene discussed is SFRP1; the disease is cancer.